JP2025510774A5 - - Google Patents
Info
- Publication number
- JP2025510774A5 JP2025510774A5 JP2024556407A JP2024556407A JP2025510774A5 JP 2025510774 A5 JP2025510774 A5 JP 2025510774A5 JP 2024556407 A JP2024556407 A JP 2024556407A JP 2024556407 A JP2024556407 A JP 2024556407A JP 2025510774 A5 JP2025510774 A5 JP 2025510774A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion polypeptide
- modified
- domain
- polypeptide according
- inclusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323417P | 2022-03-24 | 2022-03-24 | |
| US63/323,417 | 2022-03-24 | ||
| PCT/US2023/064886 WO2023183892A1 (en) | 2022-03-24 | 2023-03-23 | Sirp-alpha fusion polypeptides with modified fc domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510774A JP2025510774A (ja) | 2025-04-15 |
| JP2025510774A5 true JP2025510774A5 (https=) | 2026-03-30 |
Family
ID=86054071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024556407A Pending JP2025510774A (ja) | 2022-03-24 | 2023-03-23 | 修飾ｆｃドメインを有するｓｉｒｐ－ａｌｐｈａ融合ポリペプチド |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230365648A1 (https=) |
| EP (1) | EP4499837A1 (https=) |
| JP (1) | JP2025510774A (https=) |
| KR (1) | KR20240162572A (https=) |
| CN (1) | CN119546769A (https=) |
| AU (1) | AU2023240361A1 (https=) |
| CA (1) | CA3246192A1 (https=) |
| CL (1) | CL2024002849A1 (https=) |
| CO (1) | CO2024013909A2 (https=) |
| IL (1) | IL315706A (https=) |
| JO (1) | JOP20240212A1 (https=) |
| MX (1) | MX2024011528A (https=) |
| WO (1) | WO2023183892A1 (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2816647T3 (es) | 2012-01-17 | 2021-04-05 | Univ Leland Stanford Junior | Reactivos SIRP-alfa de alta afinidad |
| US10011660B2 (en) * | 2012-04-30 | 2018-07-03 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| PL3575326T3 (pl) * | 2012-12-17 | 2022-07-11 | Pf Argentum Ip Holdings Llc | Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc |
| WO2016023040A1 (en) | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Sirp-alpha variant constructs and uses thereof |
| PL3180363T3 (pl) | 2014-08-15 | 2020-02-28 | Merck Patent Gmbh | Białka fuzyjne immunoglobulin sirp-alfa |
| AU2016304794B2 (en) | 2015-08-07 | 2021-07-15 | ALX Oncology Inc. | Constructs having a SIRP-alpha domain or variant thereof |
| CN116239698A (zh) * | 2019-03-06 | 2023-06-09 | 江苏恒瑞医药股份有限公司 | 双功能融合蛋白及其医药用途 |
| EP3976658A4 (en) * | 2019-05-24 | 2023-06-07 | Forty Seven, Inc. | Regimes for co-administration of immunotherapeutic agents against c-kit and cd47 |
| WO2020263830A1 (en) * | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
-
2023
- 2023-03-23 IL IL315706A patent/IL315706A/en unknown
- 2023-03-23 EP EP23718588.9A patent/EP4499837A1/en active Pending
- 2023-03-23 CN CN202380038570.7A patent/CN119546769A/zh active Pending
- 2023-03-23 WO PCT/US2023/064886 patent/WO2023183892A1/en not_active Ceased
- 2023-03-23 AU AU2023240361A patent/AU2023240361A1/en active Pending
- 2023-03-23 KR KR1020247035316A patent/KR20240162572A/ko active Pending
- 2023-03-23 CA CA3246192A patent/CA3246192A1/en active Pending
- 2023-03-23 US US18/189,152 patent/US20230365648A1/en active Pending
- 2023-03-23 JP JP2024556407A patent/JP2025510774A/ja active Pending
-
2024
- 2024-09-20 MX MX2024011528A patent/MX2024011528A/es unknown
- 2024-09-24 CL CL2024002849A patent/CL2024002849A1/es unknown
- 2024-09-29 JO JOJO/P/2024/0212A patent/JOP20240212A1/ar unknown
- 2024-10-16 CO CONC2024/0013909A patent/CO2024013909A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240067757A1 (en) | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS | |
| EP2916860B1 (en) | A composition for treating diabetes comprising oxyntomodulin analog | |
| KR102041412B1 (ko) | 면역글로불린 Ｆｃ 단편 유도체 | |
| EP3576789B1 (en) | MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES | |
| ZA200005870B (en) | Binding modules derived from immunoglobulins which do not trigger complement mediated lysis. | |
| JP6162319B2 (ja) | ヒト化抗ｎ２抗体 | |
| AU2013305885A1 (en) | Molecules with antigen binding and polyvalent Fc gamma receptor binding activity | |
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| US12195543B2 (en) | Anti-FLT3 antigen binding proteins | |
| US9731007B2 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| JP2026048845A (ja) | メソテリン結合タンパク質及びその使用 | |
| EP2767548A2 (en) | Modified IgG molecules | |
| JP2025510774A5 (https=) | ||
| Lee et al. | The pharmacology study of a new recombinant TNF receptor-hyFc fusion protein | |
| KR20240113626A (ko) | 위치 429에서 돌연변이를 갖는 Fc 영역 컴포넌트를 포함하는 면역치료 단백질 | |
| CA3236737A1 (en) | Novel proteins | |
| JP2025116068A (ja) | 腎臓活性融合タンパク質及びそれを使用する治療方法 | |
| EP3623383A1 (en) | Improved bispecific flt3xcd3 antigen binding proteins | |
| US20240392035A1 (en) | Engineered anti-her2 bispecific proteins | |
| CA3111462C (en) | Improved anti-flt3 antigen binding proteins | |
| AU2024267726A1 (en) | Cd200 fusion proteins | |
| WO2025049818A1 (en) | Tnfr1 antagonists lacking agonist activity and uses thereof | |
| WO2023108101A1 (en) | Antibodies that inhibit glycoprotein ib-ix mediated platelet signaling and uses in managing bleeding conditions | |
| JP2024540220A5 (https=) |